Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.
about
A Dormant Microbial Component in the Development of PreeclampsiaA Role for Neutrophils in Viral Respiratory Disease.TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Antiviral B cell and T cell immunity in the lungs.Sustained inflammation and differential expression of interferons type I and III in PVM-infected interferon-gamma (IFNγ) gene-deleted miceMMP-12-mediated by SARM-TRIF signaling pathway contributes to IFN-γ-independent airway inflammation and AHR post RSV infection in nude miceSphingosine 1-phosphate in acute dengue infectionPriming of the Respiratory Tract with Immunobiotic Lactobacillus plantarum Limits Infection of Alveolar Macrophages with Recombinant Pneumonia Virus of Mice (rK2-PVM)S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplificationSphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.Animal models of respiratory syncytial virus infection.Sphingosine 1-Phosphate: A Novel Target for Lung Disorders.Reduction of Pertussis Inflammatory Pathology by Therapeutic Treatment With Sphingosine-1-Phosphate Receptor Ligands by a Pertussis Toxin-Insensitive Mechanism.Administration of immunobiotic Lactobacillus plantarum delays but does not prevent lethal pneumovirus infection in Rag1-/- mice.Contributions of CD8 T cells to the pathogenesis of mouse adenovirus type 1 respiratory infection.Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infectionOsteoblasts Are Rapidly Ablated by Virus-Induced Systemic Inflammation following Lymphocytic Choriomeningitis Virus or Pneumonia Virus of Mice Infection in Mice.The CD8 T Cell Response to Respiratory Virus Infections.Integrated Network Pharmacology and Metabolomics Analysis of the Therapeutic Effects of Zi Dian Fang on Immune Thrombocytopenic Purpura.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.
P2860
Q28069689-FB930D32-C13D-452A-81AF-17F7892821DEQ30234336-2C716DC6-B03F-4C13-999D-42922F327D37Q34414790-74035B90-E5CC-44F2-A66B-EA8B6AEAEC37Q34454614-46DE2037-D541-4684-A38F-811A2894402DQ34622197-1F87483B-A441-41C1-87C3-6C93C4196CA1Q35096370-915456D8-F617-4162-A4E5-50C08B9D16B1Q35435898-98B4A7AB-918E-4D33-982B-41519216A743Q36434174-AFC89521-F46C-4A0F-AF3E-2BBA7DBD3D82Q36563415-2FD5FAF3-AE92-43BF-997B-9F5D15B98CE3Q38880225-CD5BAAC8-2FAA-4993-ACFB-2CFFCA9473F3Q39026362-C556B07A-FB70-48A8-B3DA-0FEBA442B3B8Q39205808-B9A1CFE1-648C-431D-9F19-DECEB6E117A2Q39213750-1E53C372-8337-47B6-BB86-82BC0E86893EQ40157987-1FE8C5CA-617A-46FF-8AD6-9628516CBBAAQ40242166-4B61600A-ECB9-458C-8A5A-2A594D3AFE47Q40696627-45A6A925-5096-499F-9DD2-1DBC83E69C6DQ45323711-BA4CDF6A-042A-4694-9801-A98840C2BC90Q55101403-94162325-1D94-4F87-B09B-A2E815BBA6E6Q55444585-E4EA4889-06CD-4460-9883-EF3969C6A856Q55447639-80A9C3AD-95DB-44BE-9B17-88C2851D68DA
P2860
Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@ast
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@en
type
label
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@ast
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@en
prefLabel
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@ast
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@en
P2093
P2860
P356
P1433
P1476
Animal model of respiratory sy ...... te 1 receptor agonist therapy.
@en
P2093
Daniel M Fremgen
Hugh Rosen
John R Teijaro
Kevin B Walsh
Linda G Brock
Michael B A Oldstone
Peter L Collins
P2860
P304
P356
10.1128/JVI.00464-14
P577
2014-03-26T00:00:00Z